Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Request Access

Biomarkers (3)

HGB - Hemoglobin (g/dL) (phv00569523.v1.p1)
PB_PLT - Peripheral platelet Count (x1000/uL) (phv00569525.v1.p1)
PB_WBC - Peripheral WBC Count (x1000/uL) (phv00569524.v1.p1)

Demographics (3)

AGEYR_ONS - Age at study entry in years (phv00569515.v1.p1)
SEX - Sex (phv00569516.v1.p1)
SEX - Biological sex (phv00569510.v1.p1)

Race and Ethnicity (2)

ETHNIC_CAT - Ethnicity (phv00569518.v1.p1)
RACE_CAT - Race (phv00569517.v1.p1)

Other (95)

_11QG_11G - Cytogenetic finding, +11 or 11q gain (phv00569538.v1.p1)
_13QL - Cytogenetic finding, 13q loss (phv00569539.v1.p1)
_14G - Cytogenetic finding, +14 (phv00569540.v1.p1)
_1QG - Cytogenetic finding, 1q gain (phv00569531.v1.p1)
_21G - Cytogenetic finding, +21 (phv00569541.v1.p1)
_3QL - Cytogenetic finding, 3q loss (phv00569532.v1.p1)
_5PL - Cytogenetic finding, 5p loss (phv00569533.v1.p1)
_7PL - Cytogenetic finding, 7p loss (phv00569535.v1.p1)
_8G - Cytogenetic finding, +8 (phv00569537.v1.p1)
AE_ID - Unique Adverse Event Identifier (phv00569610.v1.p1)
AE_LOC_CAT - Adverse Event Category (phv00569609.v1.p1)
BMBLAST - Bone marrow blast percentage (phv00569527.v1.p1)
CHEMINTV - Prior treatment for TAM (phv00569520.v1.p1)
CNSSTAT - Central nervous system (CNS) Status (phv00569521.v1.p1)
COMPLEX_K - Complex karyotype (phv00569542.v1.p1)
CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body (phv00569509.v1.p1)
CONSORT_CAT - Consort diagram categories (phv00569513.v1.p1)
CYTO_AVAIL - Cytogenetics available? (phv00569528.v1.p1)
DYSOSR - Days to OS from relapse event (phv00569555.v1.p1)
DYSREL_ONS - Days since study entry to relapse event (phv00569551.v1.p1)
EFS1I - EFS from EOI1 indicator (phv00569546.v1.p1)
EXTMEDIS - Was the patient diagnosed with non-CNS extramedullary disease at study entry? (phv00569522.v1.p1)
MDATA01 - Targeted sequencing: Chromosome (phv00569593.v1.p1)
MDATA02 - Targeted sequencing: Start identification (phv00569594.v1.p1)
MDATA03 - Targeted sequencing: reference (Ref) (phv00569595.v1.p1)
MDATA04 - Targeted sequencing: alternative (Alt) (phv00569596.v1.p1)
MDATA05 - Targeted sequencing: Gene (phv00569597.v1.p1)
MDATA06 - Targeted sequencing: Type (phv00569598.v1.p1)
MDATA07 - Targeted sequencing: AA change (phv00569599.v1.p1)
MDATA08 - Catalogue Of Somatic Mutations In Cancer (COSMIC) (phv00569600.v1.p1)
MDATA09 - Variant allele fraction (VAF) Replicate 1 (phv00569601.v1.p1)
MDATA10 - VAF Replicate 2 (phv00569602.v1.p1)
MONO5 - Cytogenetic finding, Monosomy 5 (phv00569534.v1.p1)
MONO7 - Cytogenetic finding, Monosomy 7 (phv00569536.v1.p1)
MRPGHDX - Morphological diagnosis (phv00569543.v1.p1)
NORMAL_CYTO - Normal (constitutional trisomy 21 only) (phv00569529.v1.p1)
ORG_VIRUS - Organism/Virus Type (phv00569606.v1.p1)
ORGNAME - Organism Name (phv00569607.v1.p1)
OS1I - OS from EOI1 begin indicator (phv00569548.v1.p1)
OS1R - OS from relapse event begin indicator (phv00569556.v1.p1)
P1_BAC_INFC - Sterile site bacterial infection, grade 3 and higher (Induction I) (phv00569582.v1.p1)
P1_NEUTRO - Febrile neutropenia, grade 3 and higher (Induction I) (phv00569577.v1.p1)
P1AGNTAD - Dexrazoxane administrated (Induction I) (phv00569587.v1.p1)
P1ANCEVL - Did patient have an absolute neutrophil count (ANC) recovery during this reporting period? (Induction I) (phv00569562.v1.p1)
P1DATA - Induction I data available? (phv00569557.v1.p1)
P1DYS_ANCRCV - Days to ANC recovery (Induction I) (phv00569567.v1.p1)
P1ICUADM - Intensive care unit (ICU) admission (Induction I) (phv00569572.v1.p1)
P2_BAC_INFC - Sterile site bacterial infection, grade 3 and higher (Induction II) (phv00569583.v1.p1)
P2_NEUTRO - Febrile neutropenia, grade 3 and higher (Induction II) (phv00569578.v1.p1)
P2AGNTAD - Dexrazoxane administrated (Induction II) (phv00569588.v1.p1)
P2ANCEVL - Did patient have an ANC recovery during this reporting period? (Induction II) (phv00569563.v1.p1)
P2DATA - Induction II data available? (phv00569558.v1.p1)
P2DYS_ANCRCV - Days to ANC recovery (Induction II) (phv00569568.v1.p1)
P2ICUADM - ICU admission (Induction II) (phv00569573.v1.p1)
P3_BAC_INFC - Sterile site bacterial infection, grade 3 and higher (Induction III) (phv00569584.v1.p1)
P3_NEUTRO - Febrile neutropenia, grade 3 and higher (Induction III) (phv00569579.v1.p1)
P3AGNTAD - Dexrazoxane administrated (Induction III) (phv00569589.v1.p1)
P3ANCEVL - Did patient have an ANC recovery during this reporting period? (Induction III) (phv00569564.v1.p1)
P3DATA - Induction III data available? (phv00569559.v1.p1)
P3DYS_ANCRCV - Days to ANC recovery (Induction III) (phv00569569.v1.p1)
P3ICUADM - ICU admission (Induction III) (phv00569574.v1.p1)
P4_BAC_INFC - Sterile site bacterial infection, grade 3 and higher (Intensification I) (phv00569585.v1.p1)
P4_NEUTRO - Febrile neutropenia, grade 3 and higher (Intensification I) (phv00569580.v1.p1)
P4AGNTAD - Dexrazoxane administrated (Intensification I) (phv00569590.v1.p1)
P4ANCEVL - Did patient have an ANC recovery during this reporting period? (Intensification I) (phv00569565.v1.p1)
P4DATA - Intensification I data available? (phv00569560.v1.p1)
P4DYS_ANCRCV - Days to ANC recovery (Intensification I) (phv00569570.v1.p1)
P4ICUADM - ICU admission (Intensification I) (phv00569575.v1.p1)
P5_BAC_INFC - Sterile site bacterial infection, grade 3 and higher (Intensification II) (phv00569586.v1.p1)
P5_NEUTRO - Febrile neutropenia, grade 3 and higher (Intensification II) (phv00569581.v1.p1)
P5AGNTAD - Dexrazoxane administrated (Intensification II) (phv00569591.v1.p1)
P5ANCEVL - Did patient have an ANC recovery during this reporting period? (Intensification II) (phv00569566.v1.p1)
P5DATA - Intensification II data available? (phv00569561.v1.p1)
P5DYS_ANCRCV - Days to ANC recovery (Intensification II) (phv00569571.v1.p1)
P5ICUADM - ICU admission (Intensification II) (phv00569576.v1.p1)
PERBLSTS - Peripheral blasts (%) (phv00569526.v1.p1)
PERIOD - AAML1531 Reporting Period (phv00569605.v1.p1)
PTHTMD - History of transient myeloproliferative disorder (TAM) (phv00569519.v1.p1)
RELAPSE_SITE - Relapse site (phv00569553.v1.p1)
RR1I - Cumulative incidence of relapse (from EOI1) indicator (phv00569550.v1.p1)
SALVAGE_TX - Salvage therapy after relapse event (phv00569554.v1.p1)
SR_ELIG - Standard risk patient eligible for analysis (phv00569514.v1.p1)
STUDY - Study category (phv00569512.v1.p1)
SUBJECT_ID - Subject ID (phv00569511.v1.p1)
SUBJECT_ID - Subject ID (phv00569604.v1.p1)
SUBJECT_ID - Subject ID (phv00569508.v1.p1)
TK_MUTATION - Tyrosine kinase family gene mutation status (phv00569603.v1.p1)
TOX_DETAIL_ID - Specific toxicity details of identified patients (phv00569592.v1.p1)
TRANS_INV - Translocations and inversions recurrent in de novo acute myeloid leukemia (AML) (phv00569530.v1.p1)
TXPHASE_REL - Treatment phase of relapse event (phv00569552.v1.p1)
VIRUS - Virus Name (phv00569608.v1.p1)
YRS_FOLUP - Years follow-up for patients alive at last contact (phv00569544.v1.p1)
YRSEFS1 - Years to event-free survival (EFS) from EOI1 (phv00569545.v1.p1)
YRSOS1 - Years to overall survival (OS) from EOI1 (phv00569547.v1.p1)
YRSRR1 - Years to cumulative incidence of relapse from end of induction I (EOI1) (phv00569549.v1.p1)